The global contract manufacturing market may be showing signs of recovery but careful investment and focusing on core activities is still the most sensible approach according to Sweden-based CDMO Recipharm.
Outsourcing-pharma.com spoke with CEO Thomas Eldred at CPhI in Frankfurt in September, who set Recipharm's strategy in the context of the wider market.
Eldred also spoke about the impact the Asian contract manufacturing boom has had on the sector, explaining that the strong, consistent growth seen in countries in India and China has attracted the attention of the industry.
“I think these are markets that are very interesting to look into for the future…not so much for bringing products back to Europe but rather to explore the potential in these markets and participate in the growth.
“So that is a very important part of our future strategy and we are currently evaluating a handful of very specific opportunities that we have in these countries.”